Journal Mobile Options
Table of Contents
Vol. 45, No. 2, 2002
Issue release date: March 2002
Neuropsychobiology 2002;45:57–61
(DOI:10.1159/000048677)

Possible Role of Nitric Oxide and Adrenomedullin in Bipolar Affective Disorder

Savaş H.A. · Herken H. · Yürekli M. · Uz E. · Tutkun H. · Zoroğlu S.S. · Özen M.E. · Cengiz B. · Akyol Ö.
Departments of aPsychiatry, bChild and Adolescent Psychiatry and cPhysiology, Medical Faculty, Gaziantep University, Gaziantep, dDepartment of Molecular Biology, Art and Science Faculty, eDepartment of Biochemistry, Medical Faculty, Inonu University, Malatya, Turkey

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Nitric oxide (NO) has been implicated to play a role in the pathogenesis of depressive disorders. Adrenomedullin (AM) induces vasorelaxation by activating adenylate cyclase and also by stimulating the release of NO. AM immune reactivity is present in the brain, consistent with a role as neurotransmitter. Therefore, it is suggested that these two molecules may play a role together in the brain. We aimed to examine AM and NO in bipolar affective disorder (BPAD). Forty-four patients with BPAD and 21 healthy control subjects were included in this study. DSM-IV diagnosis of bipolar affective disorder (type I, manic episodes) was independently established by two psychiatrists and the Turkish version of the Bech-Rafaelson Mania Scale was administered. Also, a semistructured form was used to ascertain several sociodemographic and clinical variables of the patients. AM and NO were studied in plasma. The mean value of plasma NO levels in the BPAD group of 46.58 ± 13.97 µmol/l was significantly higher than that of controls (31.81 ± 8.14 µmol/l) (z = –4.15, p = 0.000). Mean plasma AM levels were found to be increased in patients with BPAD (35.13 ± 5.26 pmol/l) compared to controls (16.22 ± 3.02 pmol/l) (z = –6.16, p = 0.000). AM levels of BPAD patients were approximately 2-fold higher than controls. AM levels were positively correlated with the duration of hospitalization for the current episode and negatively correlated with the total duration of illness. Both NO and AM may have a pathophysiological role in BPAD (type I, manic episodes) and the clinical symptomatology and prognosis of BPAD.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Schulman H: Nitric oxide: A spatial second messenger. Mol Psychiatry 1997;2:296–299.

    External Resources

  2. Granner DK: Hormone action; in Murray RK, Granner DK, Mayes PA, Rodwell VW (eds): Harper’s Biochemistry. Stamford, Appleton & Lange, 1996, pp 509–521.
  3. Papageorgiou C, Grapsa E, Christodoulou NG, Zerefos N, Stamatelopoulos S, Christodoulou GN: Association of serum nitric oxide levels with depressive symptoms: A study with end-stage renal failure patients. Psychother Psychosom 2001;70:216–220.
  4. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T: Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993;192:553–560.
  5. Munoz M, Lopez JM, Sanchez-Camacho C, Moreno N, Crespo M, Gonzalez A: Comparative analysis of adrenomedullin-like immunoreactivity in the hypothalamus of amphibians. Microsc Res Tech 2001;54:173–187.
  6. Richards AM, Nicholls MG, Lewis L, Lainchbury JG: Adrenomedullin. Clin Sci (Lond) 1996;91:3–16.
  7. Shan J, Krukoff TL: Distribution of preproadrenomedullin mRNA in the rat central nervous system and its modulation by physiological stressors. J Comp Neurol 2001;432:88–100.
  8. Bernstein HG, Stanarius A, Baumann B, Henning H, Krell D, Danos P, Falkai P, Bogerts B: Nitric oxide synthase-containing neurons in the human hypothalamus: Reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 1998;83:867–875.

    External Resources

  9. Brown ES, Rush AJ, McEwen BS: Hippocampal remodeling and damage by corticosteroids: Implications for mood disorders. Neuropsychopharmacology 1999;21:474–484.

    External Resources

  10. Suzuki E, Yagi G, Nakaki T, Kanba S, Asai M: Elevated plasma nitrate levels in depressive states. J Affect Disord 2001;63:221–224.
  11. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
  12. Bech P, Bolwig TG, Kramp P, Rafaelsen OJ: The Bech-Rafaelsen Mania Scale and the Hamilton Depression Scale. Acta Psychiatr Scand 1979;59:420–430.
  13. Kantarci E, Erkoc S, Kulu D, Durmaz G, Arkonac O: Reliability and validity of Turkish version of the Bech-Rafaelsen Mania Scale; in 29th National Congress of Psychiatry of Turkey. Bursa, Savas Ofset, 1993.
  14. Evereklioglu C, Yurekli M, Er H, Ozbek E, Hazneci E, Cekmen M, Inaloz HS: Increased plasma adrenomedullin levels in patients with Behçet’s disease. Dermatology 2000;201:312–315.
  15. Hirata Y, Mitaka C, Sato K, Nagura T, Tsunoda Y, Amaha K, Marumo F: Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. J Clin Endocrinol Metab 1996;81:1449–1453.
  16. Sato K, Hirata Y, Imai T, Iwashita M, Maruo F: Characterization of immunoreactive adrenomedullin in human plasma and urine. Life Sci 1995;557:189–194.

    External Resources

  17. Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109–142.
  18. Koltuksuz U, Irmak MK, Karaman A, Uz E, Var A, Ozyurt H, Akyol O: Testicular nitric oxide levels after unilateral testicular torsion/detorsion in rats pretreated with caffeic acid phenethyl ester. Urol Res 2000;28:360–363.
  19. Cortas NK, Wakid NW: Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin Chem 1990;36:1440–1443.
  20. Fossier P, Blanchard B, Ducrocq C, Leprince C, Tauc L, Baux G: Nitric oxide transforms serotonin into an inactive form and this affects neuromodulation. Neuroscience 1999;93:597–603.
  21. Brown GC: Nitric oxide regulates mitochondrial respiration and cell functions by inhibiting cytochrome oxidase. FEBS Lett 1995;369:136–139.
  22. Shen W, Hintze TH, Wolin MS: Nitric oxide: An important signaling mechanism between vascular endothelium and parenchymal cells in the regulation of oxygen consumption. Circulation 1995;92:3505–3512.
  23. Kuo PC, Schroeder RA: The emerging multifaceted roles of nitric oxide. Ann Surg 1995;221:220–235.
  24. Szabo C, Salzman AL, Ischiropoulos H: Endotoxin triggers the expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in the rat aorta in vivo. FEBS Lett 1995;363:235–238.
  25. Kirkebóen KA, Strand OA: The role of nitric oxide in sepsis – an overview. Acta Anaesthesiol Scand 1999;43:275–288.
  26. Rubbo H, Radi R, Trujillo M, Telleri R, Kalyanaraman B, Barnes S, Kirk M, Freeman BA: Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. J Biol Chem 1994;269:26066–26075.
  27. Szabo C, Salzman AL, Ischiropoulos H: Peroxynitrite-mediated oxidation of dihydrorhodamine 123 occurs in early stages of endotoxic and hemorrhagic shock and ischemia-reperfusion injury. FEBS Lett 1995;372:229–232.
  28. Wink DA, Hanbauer I, Krishna MC, De Graff W, Gamson J, Mitchell JB: Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc Natl Acad Sci USA 1993;90:9813–9817.
  29. Deliconstantinos S, Villiotou V: NO synthase and xanthine oxidase activities of rabbit brain synaptosomes: Peroxynitrite formation as a causative factor of neurotoxicity. Neurochem Res 1996;21:51–56.

    External Resources

  30. Blum-Degen D, Heinemann T, Lan J, Pedersen V, Leblhuber F, Paulus W, Riederer P, Gerlach M: Characterization and regional distribution of nitric oxide synthase in the human brain during normal ageing. Brain Res 1999;834:128–135.

    External Resources

  31. Snyder SH, Bredt DS: Nitric oxide as a neuronal messenger. Trends Pharmacol Sci 1991;12:125–128.
  32. Dawson T, Snyder S: Gases as biological messengers: Nitric oxide and carbon monoxide in the brain. J Neurosci 1994;14:5147–5159.
  33. Beckman JS, Crow JP: Pathological implication of nitric oxide, superoxide and peroxynitrite formation. Biochem Soc Trans 1993;21:330–334.
  34. Dogan A, Suzuki Y, Koketsu N, Osuka K, Saito K, Takayasu M, Shibuya M, Yoshida J: Intravenous infusion of adrenomedullin and increase in regional cerebral blood flow and prevention of ischemic brain injury after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 1997;17:19–25.

    External Resources

  35. Samson WK, Murphy T, Schell DA: A novel vasoactive peptide, adrenomedullin, inhibits pituitary adrenocorticotropin release. Endocrinology 1995;136:2349–2352.
  36. Robertson CL, Minamino N, Ruppel RA, Kangawa K, Adelson PD, Tsuji T, Wisniewski SR, Ohta H, Janesko KL, Kochanek PM: Increased adrenomedullin in cerebrospinal fluid after traumatic brain injury in children: A preliminary report. Acta Neurochir Suppl 2000;76:419–421.

    External Resources

  37. Ceyhan BB, Karakurt S, Hekim NJ: Plasma adrenomedullin levels in asthmatic patients. J Asthma 2001;38:221–227.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50